171 related articles for article (PubMed ID: 28836148)
21. Two novel glucagon receptor antagonists prove effective therapeutic agents in high-fat-fed and obese diabetic mice.
O'Harte FP; Franklin ZJ; Irwin N
Diabetes Obes Metab; 2014 Dec; 16(12):1214-22. PubMed ID: 25060150
[TBL] [Abstract][Full Text] [Related]
22. Molecular mechanisms mediating the beneficial metabolic effects of [Arg4]tigerinin-1R in mice with diet-induced obesity and insulin resistance.
Ojo OO; Srinivasan DK; Owolabi BO; McGahon MK; Moffett RC; Curtis TM; Conlon JM; Flatt PR; Abdel-Wahab YH
Biol Chem; 2016 Aug; 397(8):753-64. PubMed ID: 26966929
[TBL] [Abstract][Full Text] [Related]
23. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
[TBL] [Abstract][Full Text] [Related]
24. The frog skin host-defense peptide CPF-SE1 improves glucose tolerance, insulin sensitivity and islet function and decreases plasma lipids in high-fat fed mice.
Srinivasan D; Ojo OO; Owolabi BO; Conlon JM; Flatt PR; Abdel-Wahab YHA
Eur J Pharmacol; 2015 Oct; 764():38-47. PubMed ID: 26123844
[TBL] [Abstract][Full Text] [Related]
25. Chemical cholecystokinin receptor activation protects against obesity-diabetes in high fat fed mice and has sustainable beneficial effects in genetic ob/ob mice.
Irwin N; Montgomery IA; Moffett RC; Flatt PR
Biochem Pharmacol; 2013 Jan; 85(1):81-91. PubMed ID: 23085436
[TBL] [Abstract][Full Text] [Related]
26. A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties.
Parthsarathy V; Irwin N; Hasib A; Martin CM; McClean S; Bhat VK; Ng MT; Flatt PR; Gault VA
Biochim Biophys Acta; 2016 Apr; 1860(4):757-64. PubMed ID: 26802310
[TBL] [Abstract][Full Text] [Related]
27. Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice.
Pathak NM; Millar PJB; Pathak V; Flatt PR; Gault VA
Mol Cell Endocrinol; 2018 Jan; 460():200-208. PubMed ID: 28754350
[TBL] [Abstract][Full Text] [Related]
28. Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.
Wang Y; Campbell T; Perry B; Beaurepaire C; Qin L
Metabolism; 2011 Feb; 60(2):298-305. PubMed ID: 20304443
[TBL] [Abstract][Full Text] [Related]
29. A novel neurotensin/xenin fusion peptide enhances β-cell function and exhibits antidiabetic efficacy in high-fat fed mice.
Perry RA; Craig SL; Gault VA; Flatt PR; Irwin N
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34370015
[TBL] [Abstract][Full Text] [Related]
30. Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice.
Tahara A; Matsuyama-Yokono A; Shibasaki M
Eur J Pharmacol; 2011 Mar; 655(1-3):108-16. PubMed ID: 21266174
[TBL] [Abstract][Full Text] [Related]
31. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
[TBL] [Abstract][Full Text] [Related]
32. Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice.
Pathak NM; Pathak V; Lynch AM; Irwin N; Gault VA; Flatt PR
Mol Cell Endocrinol; 2015 Sep; 412():95-103. PubMed ID: 26048772
[TBL] [Abstract][Full Text] [Related]
33. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice.
Ahrén B; Simonsson E; Scheurink AJ; Mulder H; Myrsén U; Sundler F
Metabolism; 1997 Jan; 46(1):97-106. PubMed ID: 9005977
[TBL] [Abstract][Full Text] [Related]
34. Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice.
Irwin N; Hunter K; Frizzell N; Flatt PR
Regul Pept; 2009 Feb; 153(1-3):70-6. PubMed ID: 19073224
[TBL] [Abstract][Full Text] [Related]
35. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
36. [D-Leu-4]-OB3 and MA-[D-Leu-4]-OB3, small molecule synthetic peptide leptin mimetics, improve glycemic control in diet-induced obese (DIO) mice.
Wang A; Anderson BM; Novakovic ZM; Grasso P
Peptides; 2018 Mar; 101():51-59. PubMed ID: 29269073
[TBL] [Abstract][Full Text] [Related]
37. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
Hata T; Mera Y; Tadaki H; Kuroki Y; Kawai T; Ohta T; Kakutani M
Diabetes Obes Metab; 2011 May; 13(5):446-54. PubMed ID: 21255216
[TBL] [Abstract][Full Text] [Related]
38. Acid Hydrolyzed Silk Peptide Consumption Improves Anti-Diabetic Symptoms by Potentiating Insulin Secretion and Preventing Gut Microbiome Dysbiosis in Non-Obese Type 2 Diabetic Animals.
Park S; Zhang T; Qiu JY; Wu X; Lee JY; Lee BY
Nutrients; 2020 Jan; 12(2):. PubMed ID: 31991596
[No Abstract] [Full Text] [Related]
39. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of action of the antidiabetic peptide [S4K]CPF-AM1 in db/db mice.
Musale V; Moffett RC; Owolabi B; Conlon JM; Flatt PR; Abdel-Wahab YHA
J Mol Endocrinol; 2021 Feb; 66(2):115-128. PubMed ID: 33252358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
